APA (7th ed.) Citation

LS, G., MB, C., B, H., AR, L., AH, S., MBN, G., . . . FK, K. (2018). GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: A randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 61(2), 413. https://doi.org/10.1007/s00125-017-4447-4

Chicago Style (17th ed.) Citation

LS, Gasbjerg, et al. "GIP(3-30)NH2 Is an Efficacious GIP Receptor Antagonist in Humans: A Randomised, Double-blinded, Placebo-controlled, Crossover Study." Diabetologia 61, no. 2 (2018): 413. https://doi.org/10.1007/s00125-017-4447-4.

MLA (9th ed.) Citation

LS, Gasbjerg, et al. "GIP(3-30)NH2 Is an Efficacious GIP Receptor Antagonist in Humans: A Randomised, Double-blinded, Placebo-controlled, Crossover Study." Diabetologia, vol. 61, no. 2, 2018, p. 413, https://doi.org/10.1007/s00125-017-4447-4.